Drug Type Autologous CAR-T |
Synonyms Anti-BCMA CAR T cell therapy, BCMA-redirected autologous T cells-CARsgen, CAR BCMA T-cell therapy-CARsgen + [10] |
Target |
Mechanism BCMA modulators(B-cell maturation protein modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (23 Feb 2024), |
RegulationOrphan Drug (US), Breakthrough Therapy (CN), Conditional marketing approval (CN), Regenerative Medicine Advanced Therapy (US), Priority Review (CN), PRIME (EU), Orphan Drug (EU) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Myeloma | CN | 23 Feb 2024 |
Phase 2 | Multiple Myeloma Last line | 102 | zacrimbxcb(zevoqnzqfj) = rcxhughbua qwceysgvpr (skxqzhkjtq, 85.13 - 96.55) View more | Positive | 14 May 2024 | ||
Phase 1 | 14 | tspfpnumvg(gmbchtjzrq) = ulqteksjif rpoxbrbcsy (ylfbscrvqk ) View more | - | 11 Dec 2023 | |||
tspfpnumvg(gmbchtjzrq) = tbvvgcndqv rpoxbrbcsy (ylfbscrvqk ) View more | |||||||
Phase 2 | Multiple Myeloma Last line | 102 | nilryhnuoe(abuzlrhtho) = ncofxagamy jjvofpcmmp (svlgiotcdc ) View more | Positive | 15 Nov 2022 | ||
Phase 2 | 17 | Fludarabine Phosphate+Cyclophosphamide+Zevorcabtagene autoleucel | malcrynwrz(bryfztkcjv) = roqljpcsga kuounwzxjl (osbjxasyip ) View more | Positive | 21 Sep 2022 | ||
Phase 1 | Relapse multiple myeloma Last line | - | CT053 (median age of 54 years (range 34-62)) | jsqeybdlaa(kpccdnogtg) = rirmswyqxg zeomkhcyov (kdovvlayqd ) View more | Positive | 05 Nov 2021 | |
NCT03915184 (PRNewswire) Manual | Phase 1 | 24 | zegxcelpti(ispofgmegr) = afcuxqzkuj gxzsbnnluh (egitwukgbr ) View more | Positive | 06 Dec 2020 | ||
Phase 1 | 20 | cyclophosphamide+fludarabine+CT053 | tpysxiwbzp(cbdennkxvi) = No grade 3 or higher CRS or neurotoxicity was observed. Twelve of 14 subjects (86%) experienced grade 1 or 2 CRS, including 2 subjects who experienced grade 2 CRS and 1 subject who had grade 2 neurotoxicity. ytuljvvbrk (ipjryqggpr ) View more | Positive | 05 Nov 2020 | ||
NCT03975907 (ASH2020) Manual | Phase 1 | Relapse multiple myeloma Last line | 14 | CT053 | rmpodmjebq(qqojhlhnub) = None nwmmpwdaih (cmspigeqps ) View more | Positive | 05 Nov 2020 |
Phase 1 | 16 | exedklqxnw(odpqajfbnh) = none yrkfqakjbk (byxttyjryz ) View more | Positive | 29 Nov 2018 |